1. Introduction {#sec1-antibiotics-08-00115}
===============

Antibiotic use and misuse has led to the emergence and development of antibiotic resistance (ABR), which is one of the biggest threats to global public health \[[@B1-antibiotics-08-00115]\]. This problem is particularly acute in China because of antibiotic prescribing behavior, including: inappropriate financial incentives, over-the-counter availability of antibiotics, and the widespread antibiotic use and misuse in agriculture \[[@B2-antibiotics-08-00115]\]. BRICS countries (Brazil, Russia, India, China and South Africa) have shown the highest rates of antibiotic use, accounting for 76% of the overall increase in global antibiotic consumption between the years 2000 and 2010. Up to 57% of the increase in the hospital sector was attributable to China \[[@B3-antibiotics-08-00115],[@B4-antibiotics-08-00115]\]. China was the second largest consumer of antibiotics in 2010. Meanwhile, China has high prescription rates of antibiotics for both inpatients and outpatients \[[@B5-antibiotics-08-00115]\]. There is also a high use of injections in China, with about one-third of the prescriptions for injections being written in community health institutions. This rate is two to three times higher than the World Health Organization (WHO) standard and estimates from other developing countries \[[@B6-antibiotics-08-00115]\].

Consequently, as a result of this antibiotic misuse, China has the highest level of ABR and the most rapid growth of ABR globally \[[@B7-antibiotics-08-00115],[@B8-antibiotics-08-00115]\]. Data from the 2017 China Antimicrobial Resistance Surveillance System showed that the national rates of methicillin-resistant *Staphylococcus aureus* (MRSA), third-generation cephalosporin-resistant *Escherichia coli*, carbapenem-resistant *Klebsiella pneumoniae* (CRKP), third-generation cephalosporin-resistant *K. pneumoniae*, carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), and carbapenem-resistant *Acinetobacter baumannii* (CRAB) were 32.2%, 54.2%, 9.0%, 33.0%, 20.7%, and 56.1%, respectively \[[@B9-antibiotics-08-00115]\], and there were regional differences across provinces in China \[[@B10-antibiotics-08-00115]\]. The report from CHINET surveillance system of bacterial resistance showed that between 2005 and 2014, carbapenem resistance among *K. pneumoniae* isolates increased from 2.4% to 13.4%, and CRAB isolates increased from 31% to 66.7% \[[@B11-antibiotics-08-00115]\].

To combat this trend, the Chinese government announced a national action plan to combat antimicrobial resistance in 2016 \[[@B12-antibiotics-08-00115]\] in response to the global action plan by WHO \[[@B13-antibiotics-08-00115]\]. On 1 July 2011, the Chinese government carried out a three-year national public hospital campaign targeting ABR \[[@B14-antibiotics-08-00115],[@B15-antibiotics-08-00115]\]. This action plan, as a combination of managerial and professional strategies, was effective in reducing antibiotic prescribing rates and intensity of antibiotic consumption. On 1 August 2012, the Chinese government formally implemented administrative regulations for the clinical use of antibacterial agents \[[@B16-antibiotics-08-00115]\]. In addition, China has built multi-disciplinary collaborations with the European Union, Sweden, the Netherlands, and the United Kingdom to stop the increasing the burden caused by ABR \[[@B14-antibiotics-08-00115]\]. Even so, we still face a great challenge in controlling antibiotic use and antibiotic resistance in China.

ABR, especially multi-drug resistance (MDR), is associated with high mortality, increased resource utilization, and additional economic costs \[[@B17-antibiotics-08-00115],[@B18-antibiotics-08-00115],[@B19-antibiotics-08-00115],[@B20-antibiotics-08-00115],[@B21-antibiotics-08-00115]\]. It is estimated that 1 million deaths will be attributed to antimicrobial resistance by 2050, and United States (US)\$20 trillion cumulative costs will be lost if substantive efforts are not made to tackle this problem \[[@B22-antibiotics-08-00115]\].

Despite the evidenced threat posed by ABR, information on its clinical and economic impact is limited in China. Assessments of the burden of ABR is a key step for the implementation of national strategies to combat ABR, so we can clearly know the costs and benefits of national action plans \[[@B13-antibiotics-08-00115]\]. However, there has not been a contemporary literature review reporting on the clinical and economic impact of ABR in mainland China. In this study, we aimed to analyze the published literature of the clinical and economic consequences of ABR or MDR bacteria compared to susceptible bacteria and uninfected individuals. We also conducted a meta-analysis of hospital mortality to quality the impact of ABR or MDR on clinical outcomes.

2. Materials and Methods {#sec2-antibiotics-08-00115}
========================

2.1. Literature Search {#sec2dot1-antibiotics-08-00115}
----------------------

A systematic search in the English databases (PubMed, Web of Science, and Embase) and Chinese databases (China National Knowledge Infrastructure, Wanfang data, and Chongqing VIP) up to 16 January 2019, was carried out. In addition, manual reference checks from retrieved studies were performed to ensure inclusion of all relevant studies. Detailed search strategies are provided in [Supplementary data 1](#app1-antibiotics-08-00115){ref-type="app"}.

2.2. Study Selection {#sec2dot2-antibiotics-08-00115}
--------------------

Inclusion criteria were (1) studies published in English or Chinese language; (2) publication date between 1 January 2000 and 16 January 2019; (3) original research using any study designs, such as cohort, case--control, or observational studies; (4) reports on humans; (5) reports in China; (6) reports on resistant versus susceptible cases; and (7) reports on clinical and economic outcomes. In order to ensure the analysis focuses on contemporary literature that reflects current resistance patterns and clinical practice guidelines, studies published before 2000 were not considered \[[@B20-antibiotics-08-00115],[@B23-antibiotics-08-00115]\]. Two reviewers (XZ, XS) independently reviewed titles and abstracts, then assessed the full-text to decide whether it met the inclusion criteria. Disagreements were resolved by a third reviewer (XH).

2.3. Data Extraction {#sec2dot3-antibiotics-08-00115}
--------------------

The extracted data included first author, publication year, type of study, method, province, hospital setting, study period, study population, types of infection, hospital ward, organisms, and sample size (cases and controls). The following outcomes were extracted: all-cause mortality, attributable mortality, 30-day (28-day) mortality, crude mortality; total hospital stay, length of stay before/after infection, intensive care unit (ICU) stay; and total hospital costs/charges, hospital costs/charges before/after infection, and antibiotic costs. All presented *p*-values were obtained from analyses within the included studies. MDR was defined that if it is resistance to three or more than three types of antibiotics or if the isolated bacteria were MDR organisms, such as MRSA, CRPA, and CRAB. In addition, both intermediate and resistant isolates were regarded as "resistant".

2.4. Study Quality Assessment {#sec2dot4-antibiotics-08-00115}
-----------------------------

We assessed the included study quality using the Newcastle-Ottawa quality assessment Scale (NOS) for cohort and case--control studies. The NOS includes four domains and nine "stars", where \>6 stars indicates high-quality studies, 4--6 stars indicates moderate quality, and ≤3 stars indicates low quality \[[@B20-antibiotics-08-00115],[@B23-antibiotics-08-00115],[@B24-antibiotics-08-00115]\] ([Table S4 and Table S5 in Supplementary data 3](#app1-antibiotics-08-00115){ref-type="app"}).

2.5. Data Analysis {#sec2dot5-antibiotics-08-00115}
------------------

Meta-analysis was conducted to determine overall mortality associated with ABR or MDR. Sub-group analyses for mortality were performed based on bacteria and three economic zones in China where there were three or more studies that could be combined. Heterogeneity was calculated as *I*^2^ statistic values, which were categorized as low (0--50%), moderate (50--75%), or high (above 75%). All values were calculated with 95% confidence intervals (CI), and the results presented as odds ratios (OR). For other outcomes, a meta-analysis was not possible due to a variety of study designs and reporting values (mean or median). Costs were converted into 2015 US dollars by annual consumer price index and 2015 average exchange rates \[[@B25-antibiotics-08-00115],[@B26-antibiotics-08-00115]\].

3. Results {#sec3-antibiotics-08-00115}
==========

3.1. Study Identification {#sec3dot1-antibiotics-08-00115}
-------------------------

A total of 13,693 studies were identified from the searches. One study was added following a hand search of the references of included studies. Of these, 8579 studies were excluded because they did not fulfill the inclusion criteria based on their title and abstracts after excluding duplicates (4770 studies). For the remaining 345 studies, we screened full texts and identified 44 potentially relevant studies ([Figure 1](#antibiotics-08-00115-f001){ref-type="fig"}).

3.2. Study Characteristics and Quality {#sec3dot2-antibiotics-08-00115}
--------------------------------------

Of the 44 eligible studies included in our review, 29 studies investigated the impact of ABR on mortality ([Table 1](#antibiotics-08-00115-t001){ref-type="table"}, [Table S1 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}), 37 studies reported on hospital length of stay or ICU stay ([Table 2](#antibiotics-08-00115-t002){ref-type="table"}, [Table S2 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}), and 21 studies reported on economic consequences ([Table 3](#antibiotics-08-00115-t003){ref-type="table"}, [Table S3 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}). The majority of studies were retrospective observational studies (43 studies) and were conducted in a single hospital setting (39 studies). The study data were obtained from 17 provinces in mainland China, with the largest number of studies from Zhejiang province (*n* = 10), followed by Shanghai (*n* = 6), Beijing (*n* = 5), Hubei (*n* = 5), Sichuan (*n* = 4), Chongqing (*n* = 3), Guangdong (*n* = 3), Jiangsu (*n* = 3), Shandong (*n* = 3), Anhui (*n* = 2), Fujian (*n* = 2), Hebei (*n* = 1), Hunan (*n* = 1), Yunnan (*n* = 1), and Ningxia (*n* = 1) ([Figure 2](#antibiotics-08-00115-f002){ref-type="fig"}). The majority of studies (*n* = 20) collected data from the eastern economic zone, and only four studies were from the central economic zone and western economic zone, respectively. Those economic zones were divided according to geographical location and economic development in China ([Figure 2](#antibiotics-08-00115-f002){ref-type="fig"}). Most of the studies (*n* = 13) reported on a group of bacteria, 11 on *A. baumannii*, 8 on *K. pneumoniae*, 8 on *S. aureus*, 5 on *P. aeruginosa*, 2 on *E. coli*, 1 on *Enterococcus*, 1 on coagulase-negative *Staphylococci*, and 1 on *Proteus mirabilis*. Statistical tests were the most utilized analysis method in the included studies, and propensity score matching, simple matching, regression model, and generalized linear model were conducted to control for baseline characteristics ([Table S1--S3 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}). Regarding the quality of included studies, 16 were high quality and 28 were moderate quality ([Table S5 in Supplementary data 3](#app1-antibiotics-08-00115){ref-type="app"}).

3.3. Mortality Outcome {#sec3dot3-antibiotics-08-00115}
----------------------

A total of 29 studies reported data on hospital mortality \[[@B27-antibiotics-08-00115],[@B28-antibiotics-08-00115],[@B29-antibiotics-08-00115],[@B30-antibiotics-08-00115],[@B31-antibiotics-08-00115],[@B32-antibiotics-08-00115],[@B33-antibiotics-08-00115],[@B34-antibiotics-08-00115],[@B35-antibiotics-08-00115],[@B36-antibiotics-08-00115],[@B37-antibiotics-08-00115],[@B38-antibiotics-08-00115],[@B39-antibiotics-08-00115],[@B40-antibiotics-08-00115],[@B41-antibiotics-08-00115],[@B42-antibiotics-08-00115],[@B43-antibiotics-08-00115],[@B44-antibiotics-08-00115],[@B45-antibiotics-08-00115],[@B46-antibiotics-08-00115],[@B47-antibiotics-08-00115],[@B48-antibiotics-08-00115],[@B49-antibiotics-08-00115],[@B50-antibiotics-08-00115],[@B51-antibiotics-08-00115],[@B52-antibiotics-08-00115],[@B53-antibiotics-08-00115],[@B54-antibiotics-08-00115],[@B55-antibiotics-08-00115]\]. We found ABR had a significant impact on mortality in 22 studies ([Table 1](#antibiotics-08-00115-t001){ref-type="table"}, [Table S1 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}). Three studies included two different comparisons based on different study designs \[[@B38-antibiotics-08-00115],[@B43-antibiotics-08-00115],[@B51-antibiotics-08-00115]\], two different comparisons contributed data for both susceptible bacterial infections and those without infections in two studies \[[@B45-antibiotics-08-00115],[@B55-antibiotics-08-00115]\], and two other studies contained two and four different descriptions of mortality (attributable or all-cause in hospital mortality/28-day (30-day) hospital mortality) \[[@B44-antibiotics-08-00115],[@B54-antibiotics-08-00115]\]. Patients with infections due to ABR or MDR bacteria had a higher odds of overall mortality than those patients with susceptible bacterial infections or control patients without infection (OR: 2.67, 95% CI: 2.18--3.26, *p* = 0.001; OR: 3.29, 95% CI: 1.71--6.33, *p* = 0.001) with moderate heterogeneity (*I^2^* = 52.5%, *P* \<0.001) ([Figure 3](#antibiotics-08-00115-f003){ref-type="fig"}A), and low heterogeneity (*I^2^* = 52.5%, *p* \<0.001), respectively ([Figure 3](#antibiotics-08-00115-f003){ref-type="fig"}B). A high risk of mortality due to ABR or MDR *P. aeruginosa* was observed with high statistical significance (OR: 3.38, 95% CI: 1.81--6.31, *p* \<0.001) with moderate heterogeneity (*I^2^* = 57.9%, *p* = 0.050), followed by gram-negative bacteria (OR: 3.30, 95% CI: 1.56--6.97, *p* = 0.002) with moderate heterogeneity (*I^2^* = 54.9%, *p* = 0.109), *K. pneumoniae* (OR: 3.12, 95% CI: 1.99--4.89, *p* \<0.001) with moderate heterogeneity (*I^2^* = 73.9%, *p* \<0.001), *A. baumannii* (OR: 2.18, 95% CI: 1.70--2.80, *p* \<0.001) with low heterogeneity (*I^2^* = 0.0%, *p* = 0.453), and *S. aureus* (OR: 1.55, 95% CI: 0.95--2.53, *p* = 0.082) with low heterogeneity (*I^2^* = 0.0%, *p* = 0.482) ([Figure 3](#antibiotics-08-00115-f003){ref-type="fig"}C). High statistical significance was observed in the central economic zone (OR: 5.14, 95% CI: 1.80--14.70, *p* = 0.002) with moderate heterogeneity (*I^2^* = 51.6%, *p* = 0.103), the eastern economic zone (OR: 2.74, 95% CI: 2.12--3.55, *p* \<0.001) with moderate heterogeneity (*I^2^* = 57.1%, *p* \<0.001), and the western economic zone (OR: 2.14, 95% CI: 1.39--3.27, *p* = 0.001) with low heterogeneity (*I^2^* = 45.2%, *p* = 0.121) ([Figure 3](#antibiotics-08-00115-f003){ref-type="fig"}D).

3.4. Hospital Stay Outcome {#sec3dot4-antibiotics-08-00115}
--------------------------

A total of 37 studies reported data on hospital stay \[[@B27-antibiotics-08-00115],[@B28-antibiotics-08-00115],[@B29-antibiotics-08-00115],[@B31-antibiotics-08-00115],[@B32-antibiotics-08-00115],[@B33-antibiotics-08-00115],[@B34-antibiotics-08-00115],[@B35-antibiotics-08-00115],[@B36-antibiotics-08-00115],[@B37-antibiotics-08-00115],[@B38-antibiotics-08-00115],[@B39-antibiotics-08-00115],[@B40-antibiotics-08-00115],[@B41-antibiotics-08-00115],[@B43-antibiotics-08-00115],[@B48-antibiotics-08-00115],[@B49-antibiotics-08-00115],[@B50-antibiotics-08-00115],[@B51-antibiotics-08-00115],[@B52-antibiotics-08-00115],[@B54-antibiotics-08-00115],[@B55-antibiotics-08-00115],[@B56-antibiotics-08-00115],[@B57-antibiotics-08-00115],[@B58-antibiotics-08-00115],[@B59-antibiotics-08-00115],[@B60-antibiotics-08-00115],[@B61-antibiotics-08-00115],[@B62-antibiotics-08-00115],[@B63-antibiotics-08-00115],[@B64-antibiotics-08-00115],[@B65-antibiotics-08-00115],[@B66-antibiotics-08-00115],[@B67-antibiotics-08-00115],[@B68-antibiotics-08-00115],[@B69-antibiotics-08-00115],[@B70-antibiotics-08-00115]\]. It is difficult to directly compare length of stay across eligible studies due to different definitions and measures (mean or median). The extra mean total length of stay ranged from 3 days between MDR gram-negative/gram-positive community-acquired infection and susceptible cases \[[@B58-antibiotics-08-00115]\], to 46 days between MDR *P. aeruginosa* and non-MDR cases \[[@B65-antibiotics-08-00115]\]. An extra median total length of stay was observed ranging from 4 days between CRPA and CSPA groups \[[@B43-antibiotics-08-00115]\] to 26 days between CRKP bloodstream infection and carbapenem-susceptible *K. pneumoniae* (CSKP) groups \[[@B43-antibiotics-08-00115]\].

Two studies reported that compared with patients without an infection, patients with MRSA infections were associated with extra median total length of stay of 14 days \[[@B56-antibiotics-08-00115]\] and extra mean total length of stay of 9 days after adjusting for confounders \[[@B36-antibiotics-08-00115]\]. Compared with patients with methicillin-susceptible *S. aureus* (MSSA), MRSA cases were associated with longer median or mean total length of stay, length of stay before infection, and length of stay after infection in univariate analyses in most studies \[[@B37-antibiotics-08-00115],[@B38-antibiotics-08-00115],[@B65-antibiotics-08-00115],[@B66-antibiotics-08-00115]\]; however, there was no significant difference between the two groups after controlling for baseline factors \[[@B38-antibiotics-08-00115]\]. We also found there was no significant difference between the two groups in univariate analyses in some studies \[[@B37-antibiotics-08-00115],[@B41-antibiotics-08-00115],[@B49-antibiotics-08-00115]\]. For other gram-positive bacteria (coagulase-negative *Staphylococci* \[[@B65-antibiotics-08-00115]\] and *Enterococcus* \[[@B54-antibiotics-08-00115]\]), there was a significant difference in hospital length of stay between resistant or MDR groups and susceptible, non-MDR, or non-infected groups in univariate analyses ([Table 2](#antibiotics-08-00115-t002){ref-type="table"}, [Table S2 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}).

Among patients with *E. coli* and *K. pneumoniae* intra-abdominal infection (IAI), one study reported longer mean total length of stay between extended spectrum βlactamases (ESBL)-positive and ESBL-negative groups (24 days vs. 15 days) in a generalized linear model \[[@B67-antibiotics-08-00115]\]. For only *K. pneumoniae* or only *E. coli*, we found significant differences in total length of stay between CRKP and non-CRKP \[[@B29-antibiotics-08-00115]\], between resistant enzyme-producing and non-resistant enzyme-producing \[[@B59-antibiotics-08-00115]\], between MDR and non-MDR \[[@B65-antibiotics-08-00115]\], and between CRKP and CSKP \[[@B49-antibiotics-08-00115],[@B51-antibiotics-08-00115]\] in univariate analyses, even after propensity score matching for potential confounding variables \[[@B51-antibiotics-08-00115]\]. We also found a significant relationship in ICU length of stay between CRKP and non-CRKP groups, and significant impacts on length of stay before infection between resistant enzyme-producing and non-resistant enzyme-producing groups and between CRKP and CSKP groups \[[@B50-antibiotics-08-00115],[@B51-antibiotics-08-00115],[@B59-antibiotics-08-00115]\]. However, there was no significant difference in total length of stay or length of stay after infection between CRKP and CSKP groups in univariate analyses \[[@B48-antibiotics-08-00115],[@B49-antibiotics-08-00115],[@B50-antibiotics-08-00115],[@B51-antibiotics-08-00115]\] ([Table 2](#antibiotics-08-00115-t002){ref-type="table"} and [Table S2 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}).

For *A. baumannii*, patients with MDR infections were associated with significantly longer mean total length of stay than non-MDR cases, ranging from 5 days for children to 13 days for adults \[[@B27-antibiotics-08-00115],[@B31-antibiotics-08-00115],[@B33-antibiotics-08-00115],[@B55-antibiotics-08-00115],[@B63-antibiotics-08-00115],[@B65-antibiotics-08-00115]\]. One study reported a 6-day additional median total length of stay for CRAB vs. carbapenem-susceptible *A. baumannii* (CSAB) \[[@B39-antibiotics-08-00115]\]. Patients with MDR *A. baumannii* or CRAB had a greater ICU length of stay than those with non-MDR *A. baumannii* \[[@B55-antibiotics-08-00115]\] or CSAB \[[@B39-antibiotics-08-00115]\], respectively. However, there was no significant difference in length of stay before infection between CRAB and CSAB groups in univariate analyses in some studies \[[@B39-antibiotics-08-00115],[@B49-antibiotics-08-00115],[@B68-antibiotics-08-00115]\]. Three studies reported length of stay among patients with *P. aeruginosa* \[[@B32-antibiotics-08-00115],[@B43-antibiotics-08-00115],[@B65-antibiotics-08-00115]\], and we found that carbapenem resistance was associated with significant impacts on total length of stay, length of stay after infection, and length of stay admitting the ICU. For patients with gram-negative and gram-positive bacteria, resistance or MDR was associated with significantly longer total length of stay or infection related length of stay than non-resistant, non-MDR, or non-infection patients \[[@B52-antibiotics-08-00115],[@B57-antibiotics-08-00115],[@B58-antibiotics-08-00115],[@B60-antibiotics-08-00115],[@B61-antibiotics-08-00115],[@B64-antibiotics-08-00115],[@B69-antibiotics-08-00115]\]. In addition, patients with carbapenem-resistant or MDR gram-negative bacteria were associated with longer hospital length of stay than those with carbapenem-susceptible or non-MDR gram-negative bacteria in two studies \[[@B34-antibiotics-08-00115],[@B62-antibiotics-08-00115]\]; however, we also found there was no significant difference in total length of stay or ICU length of stay among children with non-fermenters sepsis even after adjustment for baseline variables \[[@B40-antibiotics-08-00115]\] ([Table 2](#antibiotics-08-00115-t002){ref-type="table"}, [Table S2 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}).

3.5. Hospital Cost Outcomes {#sec3dot5-antibiotics-08-00115}
---------------------------

A total of 21 studies reported outcomes related to hospital costs or charges \[[@B27-antibiotics-08-00115],[@B28-antibiotics-08-00115],[@B38-antibiotics-08-00115],[@B39-antibiotics-08-00115],[@B40-antibiotics-08-00115],[@B43-antibiotics-08-00115],[@B44-antibiotics-08-00115],[@B51-antibiotics-08-00115],[@B52-antibiotics-08-00115],[@B56-antibiotics-08-00115],[@B57-antibiotics-08-00115],[@B58-antibiotics-08-00115],[@B60-antibiotics-08-00115],[@B61-antibiotics-08-00115],[@B63-antibiotics-08-00115],[@B64-antibiotics-08-00115],[@B65-antibiotics-08-00115],[@B67-antibiotics-08-00115],[@B68-antibiotics-08-00115],[@B69-antibiotics-08-00115],[@B70-antibiotics-08-00115]\]. Additional mean total hospital costs ranged from US\$238 among patients with ESBL-positive *E. coli*/*K. pneumoniae* IAI versus ESBL-negative cases \[[@B67-antibiotics-08-00115]\], to US\$16,496 among patients with ABR gram-positive/gram-negative bacteria versus uninfected cases \[[@B60-antibiotics-08-00115]\], and additional mean antibiotic costs ranged from US\$58 among patients with ESBL-positive *E. coli*/*K. pneumoniae* IAI versus ESBL-negative cases \[[@B67-antibiotics-08-00115]\] to US\$3240 among patients with MDR IAI versus non-MDR cases \[[@B69-antibiotics-08-00115]\] ([Table 3](#antibiotics-08-00115-t003){ref-type="table"}, [Table S3 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}).

The median total hospital cost was US\$15,763 for MRSA cases and US\$2185 for uninfected patients, accounting for an excess cost of US\$13,578 attributable to MRSA after matching on relevant variables \[[@B56-antibiotics-08-00115]\], however, there was no significant difference between MRSA and MSSA groups in two studies, whether or not they adjusting for risk factors \[[@B38-antibiotics-08-00115],[@B70-antibiotics-08-00115]\]. ESBL-positive *E. coli* or/and *K. pneumoniae* patients incurred higher total hospital costs (US\$541 vs. US\$303) and antibiotic costs (\$98 vs. US\$40) \[[@B67-antibiotics-08-00115]\]. Carbapenem-resistant *Escherichia coli* (CREC); was attributable to an extra total hospital cost of US\$2380 and US\$9851, compared with carbapenem-susceptible *E. coli* and uninfected groups, respectively \[[@B44-antibiotics-08-00115]\]. After propensity score matching, patients with CRKP had higher hospital (\$21,170 vs. US\$11,313) and antibiotic costs (\$2253 vs. US\$1251) than those with CSKP during the entire hospitalization and during the period after infection (US\$8912 vs. US\$6677; US\$973 vs. US\$573) \[[@B51-antibiotics-08-00115]\]. Patients with CRPA had a significantly higher total hospital cost and daily hospital cost than patients with CSPA in both unadjusted analysis and propensity score matching analysis \[[@B43-antibiotics-08-00115]\]. Carbapenem resistance or MDR was significantly associated with higher total hospital cost and total antibiotic cost among patients with *A. baumannii* after accounting for confounding factors \[[@B27-antibiotics-08-00115],[@B39-antibiotics-08-00115],[@B63-antibiotics-08-00115],[@B68-antibiotics-08-00115]\]. In addition, patients with resistant or MDR gram-negative and/or gram-positive bacteria were associated with higher total hospital costs and antibiotic costs than those with susceptible, non-MDR, or uninfected cases in most of studies \[[@B28-antibiotics-08-00115],[@B40-antibiotics-08-00115],[@B52-antibiotics-08-00115],[@B57-antibiotics-08-00115],[@B60-antibiotics-08-00115],[@B61-antibiotics-08-00115],[@B64-antibiotics-08-00115],[@B69-antibiotics-08-00115]\]; however, there was no significant difference in total hospital cost between MDR gram-negative bacteria and non-MDR gram-negative bacteria in a univariate analysis in one study \[[@B28-antibiotics-08-00115]\]. One study found that patients with MDR *E. coli*, *K. pneumoniae*, *Proteus mirabilis*, *A. baumannii*, *P. aeruginosa*, *Enterobacter cloacae*, *S. aureus*, or coagulase-negative *Staphylococci* were associated with significantly higher total hospital costs than non-MDR cases in univariate analyses \[[@B65-antibiotics-08-00115]\] ([Table 3](#antibiotics-08-00115-t003){ref-type="table"}, [Table S3 in Supplementary data 2](#app1-antibiotics-08-00115){ref-type="app"}).

4. Discussion {#sec4-antibiotics-08-00115}
=============

ABR is a global health crisis, especially in China, with high prescription rates for antibiotics in both inpatients and outpatients coupled with the highest level growth of ABR globally \[[@B8-antibiotics-08-00115]\]. To our knowledge, this is the first systematic review to analyze the clinical and economic impact of ABR in China. It provides a clear picture of the real-world clinical and economic outcomes among patients with ABR, especially MDR, for clinicians, patients and researchers by merging information from both Chinese and English studies.

ABR and MDR are associated with significantly increased overall mortality as compared with susceptibility and non-infection (OR: 2.67, 95% CI: 2.18--3.26, *p* = 0.001; OR: 3.29, 95% CI: 1.71--6.33, *p* = 0.001, respectively), based on the pooled crude effect estimate, even though we found there was no significant difference between ABR or MDR and mortality in some studies, which is consistent with several studies in high-income, middle-income, and low-income countries \[[@B18-antibiotics-08-00115],[@B20-antibiotics-08-00115],[@B23-antibiotics-08-00115],[@B71-antibiotics-08-00115],[@B72-antibiotics-08-00115],[@B73-antibiotics-08-00115],[@B74-antibiotics-08-00115],[@B75-antibiotics-08-00115],[@B76-antibiotics-08-00115]\]. This result may be overestimated because of the fact that most of patients with ABR, especially MDR, present with other mortality risk factors such as: severe illness, prolonged stay, ICU admission, invasive devices, and inappropriate antibiotic treatment. Therefore, this finding should be interpreted with caution as we did not adjust for such potential confounding factors.

We suggest that ABR is not always, but usually, associated with significantly longer length of stay and higher hospital costs, which is consistent with other review studies \[[@B18-antibiotics-08-00115],[@B20-antibiotics-08-00115],[@B23-antibiotics-08-00115]\]. Some studies may have lacked sufficient statistical power to detect significant differences in hospital stay and hospital costs. We found that a large number of studies addressing hospital stay or hospital costs calculated the mean or median values for different groups and performed univariate comparisons, with the results for different groups being more conservative after controlling baseline factors than univariate comparisons \[[@B38-antibiotics-08-00115],[@B43-antibiotics-08-00115],[@B51-antibiotics-08-00115]\]; therefore, these results need to be interpreted with caution. Propensity scoring matching, simple matching, and multivariate analysis were the common methods used by studies to reduce the impact of potential confounding \[[@B27-antibiotics-08-00115],[@B36-antibiotics-08-00115],[@B38-antibiotics-08-00115],[@B39-antibiotics-08-00115],[@B40-antibiotics-08-00115],[@B43-antibiotics-08-00115],[@B51-antibiotics-08-00115],[@B56-antibiotics-08-00115],[@B57-antibiotics-08-00115],[@B60-antibiotics-08-00115],[@B63-antibiotics-08-00115],[@B68-antibiotics-08-00115]\]. Some studies reported that ICU stay was associated with MDR \[[@B49-antibiotics-08-00115],[@B51-antibiotics-08-00115]\]. The airborne and contact transmission of ABR bacteria in the ICU may result in healthcare-acquired infections among patients admitted to the ICU, especially for critically ill or immunocompromised patients who are associated with prolonged ICU stays, more invasive procedures, and greater exposure to more broad spectrum antibiotics \[[@B48-antibiotics-08-00115],[@B50-antibiotics-08-00115]\]. This in turn likely contributes to higher mortality \[[@B50-antibiotics-08-00115]\], longer hospital stay, and higher hospital costs \[[@B67-antibiotics-08-00115]\]. These consequences further increase the likelihood of the spread of MDR bacteria.

There were vast differences in both clinical and economic outcomes in different studies, which may be related to differences in consumption of classes of antibiotics, resistance patterns, and implementation of antibiotic stewardship programs in different provinces. China is extensive, with rich resources, and there are large differences in terms of the natural environment, socio-economic conditions, medical resources, medical conditions, health consciousness, and habits of medical treatment in different provinces. It is required that health authorities of different provinces develop antibiotic lists that meet local conditions \[[@B77-antibiotics-08-00115]\]. Research with large sample sizes and multiple hospital settings on a national level and regional level is needed in the future in order to provide information for implementation of regional or national strategies for the containment of ABR, and to make a contribution to the global action plan on ABR. The report from the 2017 China Antimicrobial Resistance Surveillance showed that there were various differences in the morbidity from ABR or MDR in different provinces across mainland China. The detection rate of MRSA ranged from 16.6% in Shanxi province to 52% in the Tibet autonomous region. The resistance rate of CREC, third-generation cephalosporin-resistant *K. pneumoniae*, CRPA, and CRAB ranged from 0.3% in the Tibet autonomous region to 2.8% in Liaoning province, from 14.1% in Qinghai province to 53.8% in Henan province, from 8.7% in Ningxia Hui Autonomous Region to 30.2% in Liaoning province, and from 23.3% in Qinghai province to 80.4% in Henan province, respectively \[[@B10-antibiotics-08-00115]\]. Therefore, the clinical and economic outcomes of ABR in different provinces, especially those that were not referred to in this study, but associated with high resistance rate, should attract the attention of researchers. *Enterococcus* and *E. coli*, defined as priority ABR bacteria by the WHO should gain further attention in China \[[@B10-antibiotics-08-00115]\]. Methodological choices, description of values, target bacteria, and comparison groups can also lead to extreme variations in clinical and economic outcomes which studies reported.

In addition, there was geographical heterogeneity of studies reporting on clinical and economic outcomes in China. The most studies are limited chiefly to eastern economic zone, which is the most developed zone in China. Its consistent with the situation that similar analyses are needed for low- and middle- income countries \[[@B13-antibiotics-08-00115]\]. The current status of ABR or MDR may be more serious in central and western economic zone because of lack of new medicines, diagnostic tools, and interventions. Moreover, compared with eastern economic zone, ABR or MDR in central and western economic zone may be associated with a higher mortality rate and higher economic burden, and a greater likelihood extreme poverty \[[@B78-antibiotics-08-00115]\]; thus, the overall clinical and economic burden of ABR or MDR in China may be underestimated.

Our study has several limitations. First, it should be noted that varying study designs, including study population, sample size, hospital setting, infection type, and hospital ward could influence the clinical and economic outcomes. However, most of included studies did not differentiate which of these culture results represented true infection or colonization. Colonization, as an important reservoir for strains causing healthcare-associated infections, should be considered in future research. In addition, only study one was prospective, and the nature of retrospective studies means they may result in missing data and selection bias. Only published literatures were included, and potential publication bias cannot be neglected. Lastly, we could not conduct a meta-analysis for hospital stay and hospital costs due to a variety of reporting values (mean or median).

5. Conclusions {#sec5-antibiotics-08-00115}
==============

Our study indicates that ABR is associated with significantly higher mortality, whether in unadjusted or adjusted analyses. Moreover, ABR is not always, but usually, associated with significantly longer hospital stay and higher hospital costs. It is possible to lack statistical power to detect significant differences; however, the results without adjustments for confounding factors need to be interpreted with caution. The review also highlights key areas where further research is needed in China: there is a need for prospective studies with multiple settings, with a societal perspective, and large sample size. In addition, a standardized and localized definition about ABR or MDR is necessary in China. Research is needed in the future, focusing on other bacteria (e.g., *Enterococcus*, *E. coli*) and colonized bacteria as well.
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Forest plot of impact of antibiotic resistance on mortality and sub-group analyses. (**A**) Forest plot of overall mortality of antibiotic resistance compared to those with susceptibility. (**B**) Forest plot of overall mortality of antibiotic resistance compared to those without infection. (**C**) Forest plot of overall mortality of antibiotic resistance compared to those with susceptibility based on bacteria. (**D**) Forest plot of overall mortality of antibiotic resistance compared to those with susceptibility based on economic zones (eastern economic zone, central economic zone, and western economic zone). OR: odds ratio; CI: confidence intervals; PA: *Pseudomonas aeruginosa*; MDRPA: multi-drug resistant *P. aeruginosa*; GP/GN: gram-positive/negative bacteria; IRAB: imipenem-resistant *Acinetobacter baumannii*; ISAB: imipenem-susceptible *A. baumannii*; MDRAB: multi-drug resistant *A. baumannii*; CRAB: carbapenem-resistant *A. baumannii*; CSAB: carbapenem-susceptible *A. baumannii*; MDR GP/GN: multi-drug resistant gram-positive/negative bacteria; CRGN: carbapenem-resistant gram-negative bacteria; CSGN: carbapenem-susceptible gram-negative bacteria; CRKP: carbapenem-resistant *Klebsiella pneumoniae*; CSKP: carbapenem-susceptible *K. pneumoniae*; CRPA: carbapenem-resistant *P. aeruginosa*; CSPA: carbapenem-susceptible *P. aeruginosa*; LNSE: linezolid non-susceptible *Enterococcus*; LSE: linezolid-susceptible *Enterococcus*; MRSA: methicillin-resistant *Staphylococcus aureus*; MSSA: methicillin-susceptible *S. aureus*; CREC: carbapenem-resistant *Escherichia coli*; CSEC: carbapenem-susceptible *E. coli*; CNSKP: carbapenem non-susceptible *K. pneumoniae*; MDRGN: multi-drug resistant gram-negative bacteria.
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###### 

Studies describing hospital mortality among inpatients with antibiotic resistance and multi-drug resistance.

  Author                                         Year                              Bacteria                                 Comparison Group               Sample Size                 Description of Mortality   Mortality Rate   *p*-Value                                               
  ---------------------------------------------- --------------------------------- ---------------------------------------- ------------------------------ --------------------------- -------------------------- ---------------- --------------------------- ----- -------- ---- ------- ---------
  Guo et al. \[[@B27-antibiotics-08-00115]\]     2017                              *A. baumannii*                           MDR                            non-MDR                     122                        366              in hospital mortality       7     5.74     22   6.01    0.912
  Hu et al. \[[@B28-antibiotics-08-00115]\]      2014                              gram-negative                            MDR                            non-MDR                     89                         165              30-day hospital mortality   23    25.8     25   15.2    \<0.05
  Huang \[[@B29-antibiotics-08-00115]\]          2015                              *K. pneumoniae*                          CRKP                           non-CRKP                    113                        77               in hospital mortality       53    46.9     26   33.77   0.07
  Li et al. \[[@B30-antibiotics-08-00115]\]      2014                              gram-negative/gram positive              MDR                            non-MDR                     62                         473              in hospital mortality       5     8.07     12   2.54    \<0.05
  Liang \[[@B31-antibiotics-08-00115]\]          2014                              *A. baumannii*                           MDR                            non-MDR                     68                         53               in hospital mortality       13    19.12    3    5.66    0.03
  Lv et al. \[[@B32-antibiotics-08-00115]\]      2015                              *P. aeruginosa*                          CRPA                           CSPA                        32                         68               in hospital mortality       2     13.33    1    1.79    \<0.05
  Pei \[[@B33-antibiotics-08-00115]\]            2015                              *A. baumannii*                           MDR                            non-MDR                     226                        65               in hospital mortality       80    35.4     13   20      0.019
  Wang \[[@B34-antibiotics-08-00115]\]           2018                              gram-negative                            carbapenem resistance          carbapenem susceptibility   26                         113              28-day hospital mortality   13    50       15   13.3    \<0.001
  Wang et al. \[[@B35-antibiotics-08-00115]\]    2016                              *A. baumannii*                           CRAB                           CSAB                        97                         145              in hospital mortality       44    45.6     43   29.9    0.02
  Zhang et al. \[[@B36-antibiotics-08-00115]\]   2013                              *S. aureus*                              MRSA                           without infection           192                        384              in hospital mortality       21    10.94    17   4.43    0.03
  Zhou et al. \[[@B37-antibiotics-08-00115]\]    2015                              *S. aureus*                              MRSA                           MSSA                        91                         266              in hospital mortality       12    13.19    24   9.02    0.26
  Chen et al. \[[@B38-antibiotics-08-00115]\]    2016                              *S. aureus*                              MRSA                           MSSA                        75                         78               in hospital mortality       13    17.33    7    8.97    0.131
  46                                             46                                in hospital mortality                    5                              10.87                       7                          15.22            0.385                                                   
  Cui et al. \[[@B39-antibiotics-08-00115]\]     2012                              *A. baumannii*                           IRAB                           ISAB                        138                        138              in hospital mortality       54    39.1     28   20.3    \<0.01
  Long et al. \[[@B40-antibiotics-08-00115]\]    2015                              Gram-negative                            carbapenem resistance          carbapenem susceptibility   34                         34               in hospital mortality       16    47.1     7    20.6    0.021
  Zhu et al. \[[@B41-antibiotics-08-00115]\]     2016                              *S. aureus*                              MRSA                           MSSA                        22                         42               in hospital mortality       6     27.3     6    14.3    0.312
  Yang et al. \[[@B42-antibiotics-08-00115]\]    2018                              *A. baumannii*                           CRAB                           CSAB                        84                         34               in hospital mortality       23    27.4     2    5.9     0.011
  84                                             34                                30-day hospital mortality                13                             15.5                        2                          5.9              0.025                                                   
  Chen et al. \[[@B43-antibiotics-08-00115]\]    2018                              *P. aeruginosa*                          CRPA                           CSPA                        327                        472              in hospital mortality       51    15.6     30   6.4     \<0.001
  270                                            270                               in hospital mortality                    34                             12.6                        21                         7.8              0.044                                                   
  Meng et al. \[[@B44-antibiotics-08-00115]\]    2017                              *E. coli*                                CREC                           CSEC                        49                         96               in hospital mortality       6     12       1    1       0.01
  CREC                                           without infection                 49                                       96                             in hospital mortality       6                          12               1                           1     0.01                  
  Zheng et al. \[[@B45-antibiotics-08-00115]\]   2013                              *A. baumannii*                           CRAB                           CSAB                        97                         145              28-day hospital mortality   44    45.6     43   29.9    0.02
  Yuan et al. \[[@B46-antibiotics-08-00115]\]    2017                              *P. aeruginosa*                          CRPA                           CSPA                        85                         94               in hospital mortality       14    16.5     1    1.1     \<0.001
  Xiao et al. \[[@B47-antibiotics-08-00115]\]    2018                              *K. pneumoniae*                          CNSKP                          CSKP                        135                        293              30-day hospital mortality   79    58.5     45   15.4    \<0.001
  Wang et al. \[[@B48-antibiotics-08-00115]\]    2018                              *K. pneumoniae*                          CRKP                           CSKP                        48                         48               in hospital mortality       23    47.9     2    4.2     0.03
  Tian et al. \[[@B49-antibiotics-08-00115]\]    2016                              *K. pneumoniae*                          CRKP                           CSKP                        33                         81               in hospital mortality       14    42.4     16   19.8    0.013
  33                                             81                                28-day hospital mortality                11                             33.3                        15                         18.5             0.087                                                   
  33                                             81                                attributable 28-day hospital mortality   11                             33.3                        13                         16               0.04                                                    
  33                                             81                                attributable in hospital mortality       14                             42.4                        14                         24.6             0.005                                                   
  Jiao et al. \[[@B50-antibiotics-08-00115]\]    2015                              *K. pneumoniae*                          CRKP                           CSKP                        30                         30               in hospital mortality       10    33.3     5    16.7    \>0.05
  Huang et al. \[[@B51-antibiotics-08-00115]\]   2018                              *K. pneumoniae*                          CRKP                           CSKP                        237                        237              in hospital mortality       32    13.5     25   10.55   0.324
  237                                            1328                              in hospital mortality                    39                             14.61                       75                         5.65             \<0.001                                                 
  Yang et al. \[[@B52-antibiotics-08-00115]\]    2009                              gram-positive/gram-negative              resistance                     non-resistance              676                        732              in hospital mortality       79    11.7     40   5.4     \<0.001
  Cao et al. \[[@B53-antibiotics-08-00115]\]     2004                              *P. aeruginosa*                          MDR *P. aeruginosa*            susceptibility              44                         68               in hospital mortality       24    54.5     11   16.2    \<0.05
  Jia et al. \[[@B54-antibiotics-08-00115]\]     2015                              *Enterococcus*                           linezolid non-susceptibility   linezolid susceptibility    44                         44               in hospital mortality       3     6.8      2    4.5     \>0.05
  linezolid non-susceptibility                   Inpatients during the same time   44                                       176                            in hospital mortality       3                          6.8              3                           1.7   \>0.05                
  Cai et al. \[[@B55-antibiotics-08-00115]\]     2012                              *A. baumannii*                           MDR                            non-MDR                     115                        45               in hospital mortality       21    18.26    2    4.44    \<0.05

*A. baumannii*: *Acinetobacter baumannii*; *K. pneumoniae*: *Klebsiella pneumoniae*; *P. aeruginosa*: *Pseudomonas aeruginosa*; *S. aureus*: *Staphylococcus aureus*; *E. coli*: *Escherichia coli*; MDR: multi-drug resistance; CRKP: carbapenem-resistant *K. pneumoniae*; CSKP: carbapenem-susceptible *K. pneumoniae*; CRPA: carbapenem-resistant *P. aeruginosa*; CSPA: carbapenem-susceptible *P. aeruginosa*; CRAB: carbapenem-resistant *A. baumannii*; CSAB: carbapenem-susceptible *A. baumannii*; IRAB: imipenem-resistant *A. baumannii*; ISAB: imipenem-susceptible *A. baumannii*; MRSA: methicillin-resistant *S. aureus*; MSSA: methicillin-susceptible *S. aureus*; CREC: carbapenem-resistant *E. coli*; CSEC: carbapenem-susceptible *E. coli*; CNSKP: carbapenem non-susceptible *K. pneumoniae*.
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###### 

Studies describing hospital stay among patients with antibiotic resistance and multi-drug resistance.

  Author                                         Year                              Bacteria                      Comparison Group              Sample Size                       Description of LOS   LOS         *p*-Value                                                                                
  ---------------------------------------------- --------------------------------- ----------------------------- ----------------------------- --------------------------------- -------------------- ----------- ------------------------- ---------------- ---------- ----------- --------- ------------ ---------
  Fu et al. \[[@B56-antibiotics-08-00115]\]      2014                              *S. aureus*                   MRSA                          without infection                 456                  706         total LOS                 median (Q)       31         42          16        14           0.001
  Guo et al. \[[@B27-antibiotics-08-00115]\]     2017                              *A. baumannii*                MDR                           non-MDR                           122                  366         total LOS                 mean (SD)        24         17          11        9            \<0.001
  median (Q1-Q3)                                 19                                (13--29)                      9                             (5--15)                           \<0.001                                                                                                                   
  Hu et al. \[[@B28-antibiotics-08-00115]\]      2014                              gram-negative                 MDR                           non-MDR                           89                   165         total LOS                 median (IQR)     24         (18--39)    25        (17--52)     \>0.05
  Huang \[[@B29-antibiotics-08-00115]\]          2015                              *K. pneumoniae*               CRKP                          non-CRKP                          113                  77          total LOS                 mean (SD)        70         69          32        34           \<0.000
  ICU LOS                                        mean (SD)                         59                            70                            22                                33                   \<0.001                                                                                              
  Jiang et al. \[[@B57-antibiotics-08-00115]\]   2016                              gram-negative/gram-positive   MDR                           non-MDR                           41                   41          total LOS                 median (Q)       24         25          19        14           0.01
  Li et al. \[[@B58-antibiotics-08-00115]\]      2018                              gram-negative/gram-positive   MDR                           susceptibility                    78                   78          total LOS                 mean (SD)        14         6           11        3            \<0.001
  Li et al. \[[@B59-antibiotics-08-00115]\]      2016                              *K. pneumoniae*               resistant enzymes producing   non-resistant enzymes producing   41                   80          total LOS                 mean (SD)        22         17          14        9            0.003
  LOS before infection                           mean (SD)                         8                             8                             5                                 5                    0.017                                                                                                
  Liang \[[@B31-antibiotics-08-00115]\]          2014                              *A. baumannii*                MDR                           non-MDR                           68                   53          total LOS                 mean (SD)        24         10          14        5            0.002
  Liu \[[@B60-antibiotics-08-00115]\]            2018                              gram-negative/gram-positive   antibiotic resistance         without nosocomial infection      133                  133         total LOS                 mean             68                     28                     \<0.05
  Lv et al. \[[@B32-antibiotics-08-00115]\]      2015                              *P. aeruginosa*               CRPA                          CSPA                              32                   68          LOS after admitting ICU   mean (SD)        11         1           3         1            0.01
  Pan et al. \[[@B61-antibiotics-08-00115]\]     2018                              gram-negative/gram-positive   MDR                           susceptibility                    102                  79          total LOS                 mean (SD)        36         22          29        18           0.026
  Pei \[[@B33-antibiotics-08-00115]\]            2015                              *A. baumannii*                MDR                           non-MDR                           226                  65          total LOS                 mean (SD)        35         25          27        17           0.002
  Wang \[[@B34-antibiotics-08-00115]\]           2018                              gram-negative                 carbapenem resistance         carbapenem susceptibility         26                   113         LOS before infection      median (IQR)     19         (3--42)     3         (0--13)      \<0.001
  Jiang \[[@B62-antibiotics-08-00115]\]          2018                              gram-negative                 MDR                           non-MDR                           79                   79          total LOS                 mean (SD)        19         15          13        7            \<0.05
  LOS before infection                           mean (SD)                         10                            5                             9                                 7                    \<0.05                                                                                               
  Wang et al. \[[@B35-antibiotics-08-00115]\]    2016                              *A. baumannii*                CRAB                          CSAB                              97                   145         LOS before pneumonia      mean (SD)        18         6           18        7            0.38
  Wu et al. \[[@B63-antibiotics-08-00115]\]      2018                              *A. baumannii*                MDR                           non-MDR                           65                   65          total LOS                 median (Q)       52         42          27        21           \<0.01
  Xing et al. \[[@B64-antibiotics-08-00115]\]    2017                              gram-negative/gram-positive   MDR                           without infection                 178                  178         total LOS                 median (IQR)     32         (23--47)    12        (9--27)      \<0.001
  Xu et al. \[[@B65-antibiotics-08-00115]\]      2017                              *E. coli*                     MDR                           non-MDR                           969                  1940        total LOS                 mean (SD)        19         23          13        12           \<0.001
  *K. pneumoniae*                                MDR                               non-MDR                       186                           529                               total LOS            mean (SD)   19                        16               15         14          0.03                   
  *Proteus mirabilis*                            MDR                               non-MDR                       38                            60                                total LOS            mean (SD)   25                        22               14         9           0.002                  
  *A. baumannii*                                 MDR                               non-MDR                       53                            45                                total LOS            mean (SD)   22                        21               16         11          0.045                  
  *P. aeruginosa*                                MDR                               non-MDR                       13                            490                               total LOS            mean (SD)   64                        43               18         17          \<0.001                
  *Enterobacter cloacae*                         MDR                               non-MDR                       94                            166                               total LOS            mean (SD)   29                        31               18         19          0.001                  
  *S. aureus*                                    MDR                               non-MDR                       41                            237                               total LOS            mean (SD)   21                        18               14         15          0.008                  
  coagulase-negative *Staphylococci*             MDR                               non-MDR                       76                            184                               total LOS            mean (SD)   26                        26               18         16          0.002                  
  Yu \[[@B66-antibiotics-08-00115]\]             2016                              *S. aureus*                   MRSA                          MSSA                              118                  116         total LOS                 median           33                     14                     \<0.05
  Zhang et al. \[[@B36-antibiotics-08-00115]\]   2013                              *S. aureus*                   MRSA                          without infection                 192                  384         total LOS                 mean (SD)        27         9           18        9            \<0.01
  Zhou et al. \[[@B37-antibiotics-08-00115]\]    2015                              *S. aureus*                   MRSA                          MSSA                              91                   266         total LOS                 median (IQR)     29         (21--60)    23        (15--42)     \<0.01
  LOS before infection                           median (IQR)                      11                            (4--23)                       3.5                               (0--13)              \<0.01                                                                                               
  LOS after infection                            median (IQR)                      17                            (7--31)                       16.5                              (8--29)              0.92                                                                                                 
  Chen et al. \[[@B38-antibiotics-08-00115]\]    2016                              *S. aureus*                   MRSA                          MSSA                              75                   78          total LOS                 median (IQR)     40         (20--94)    28        (21--53)     0.003
  46                                             46                                total LOS                     median (IQR)                  28                                (21--52)             28          (21--53)                  0.899                                                          
  75                                             78                                LOS after infection           median (IQR)                  19                                (10--46)             17          (8--29)                   0.011                                                          
  46                                             46                                LOS after infection           median (IQR)                  15                                (9--25)              17          (8--29)                   0.676                                                          
  Cui et al. \[[@B39-antibiotics-08-00115]\]     2012                              *A. baumannii*                IRAB                          ISAB                              138                  138         total LOS                 median (IQR)     29         (19--57)    23        (15--39)     \<0.01
  ICU LOS                                        median (IQR)                      15                            (8--28)                       0                                 (0--10)              \<0.01                                                                                               
  LOS before infection                           median (IQR)                      10                            (4--20)                       13                                (7--20)              \>0.05                                                                                               
  Long et al. \[[@B40-antibiotics-08-00115]\]    2015                              gram-negative                 carbapenem resistance         carbapenem susceptibility         34                   34          total LOS                 mean (SD)        28         3           22        2            \>0.05
  ICU LOS                                        mean (SD)                         17                            3                             13                                3                    \>0.05                                                                                               
  Zhu et al. \[[@B41-antibiotics-08-00115]\]     2016                              *S. aureus*                   MRSA                          MSSA                              22                   42          total LOS                 mean (SD)        26         23          15        11           0.062
  Hu et al. \[[@B67-antibiotics-08-00115]\]      2010                              *E. coli*/*Klebsiella spp.*   ESBL-positive                 ESBL-negative                     32                   53          total LOS                 mean             24                     15                     0.001
  Zhen et al. \[[@B68-antibiotics-08-00115]\]    2017                              *A. baumannii*                CRAB                          CSAB                              2126                 854         LOS before infection      mean (SD)        10         16          11        28           0.057
  Zhen et al. \[[@B69-antibiotics-08-00115]\]    2018                              gram-negative/gram-positive   MDR                           non-MDR                           64                   37          total LOS                 mean (SD)        31         29          16        13           \<0.000
  Chen et al. \[[@B43-antibiotics-08-00115]\]    2018                              *P. aeruginosa*               CRPA                          CSPA                              327                  472         total LOS                 median (IQR)     29         (17--44)    21        (11--34)     \<0.001
  270                                            270                               total LOS                     median (IQR)                  29                                (17--42)             26          (14--41)                  0.026                                                          
  327                                            472                               LOS after infection           median (IQR)                  17                                (8--32)              13          (7--25)                   0.005                                                          
  270                                            270                               LOS after infection           median (IQR)                  19                                (8--30)              14          (7--28)                   0.029                                                          
  Wang et al. \[[@B48-antibiotics-08-00115]\]    2018                              *K. pneumoniae*               CRKP                          CSKP                              48                   48          total LOS                 median (IQR)     84         (41--188)   33        (21--60)     0.097
  Tian et al. \[[@B49-antibiotics-08-00115]\]    2016                              *K. pneumoniae*               CRKP                          CSKP                              33                   81          total LOS                 median (IQR)     50         (28--83)    24        (16.5--51)   0.001
  LOS after infection                            median (IQR)                      24                            (10--51)                      15                                (9--28)              0.066                                                                                                
  Jiao et al. \[[@B50-antibiotics-08-00115]\]    2015                              *K. pneumoniae*               CRKP                          CSKP                              30                   30          total LOS                 mean (SD)        34         31          18        23           0.054
  LOS before infection                           mean (SD)                         34                            31                            13                                27                   0.02                                                                                                 
  Huang et al. \[[@B51-antibiotics-08-00115]\]   2018                              *K. pneumoniae*               CRKP                          CSKP                              237                  237         total LOS                 median (range)   31         (22--55)    24        (14--46)     \<0.001
  237                                            1328                              total LOS                     median (range)                31                                (22--56)             19          (11--35)                  \<0.001                                                        
  237                                            1328                              LOS before infection          median (range)                13                                (2--25)              3           (0--11)                   \<0.001                                                        
  237                                            1328                              LOS after infection           median (range)                21                                (10--44)             18          (9--46)                   0.612                                                          
  Yang et al. \[[@B52-antibiotics-08-00115]\]    2009                              gram-negative/gram-positive   resistance                    non-resistance                    676                  732         total LOS                 mean (SD)        34         39          18        24           \<0.001
  total LOS                                      median                            21                                                          12                                                     \<0.001                                                                                              
  infection related LOS                          mean (SD)                         22                            21                            12                                13                   \<0.001                                                                                              
  infection related LOS                          median                            15                                                          9                                                      \<0.001                                                                                              
  Li et al. \[[@B70-antibiotics-08-00115]\]      2016                              *S. aureus*                   MRSA                          MSSA                              14                   61          total LOS                 mean (SD)        38         47          19        14           0.12
  total LOS                                      median                            19                                                          15                                                     0.12                                                                                                 
  Jia et al. \[[@B54-antibiotics-08-00115]\]     2015                              *Enterococcus*                linezolid nonsusceptibility   linezolid susceptibility          44                   44          total LOS                 median (IQR)     37         (15--57)    22        (9--43)      \<0.05
  linezolid nonsusceptibility                    inpatients during the same time   44                            176                           total LOS                         median (IQR)         37          (15--57)                  17               (11--28)   \<0.05                             
  linezolid nonsusceptibility                    linezolid susceptibility          44                            44                            LOS after infection               median (IQR)         8           (3--15)                   5                (3--20)    \<0.05                             
  linezolid nonsusceptibility                    inpatients in the same time       44                            176                           LOS after infection               median (IQR)         8           (3--15)                   4                (1--12)    \<0.05                             
  Cai et al. \[[@B55-antibiotics-08-00115]\]     2012                              *A. baumannii*                MDR                           non-MDR                           115                  45          total LOS                 mean (SD)        19         9           14        4            0.001
  ICU LOS                                        mean (SD)                         17                            7                             14                                4                    0.009                                                                                                

*S. aureus*: *Staphylococcus aureus*; *A. baumannii*: *Acinetobacter baumannii*; *K. pneumoniae*: *Klebsiella pneumoniae*; *P. aeruginosa*: *Pseudomonas aeruginosa*; *E. coli*: *Escherichia coli*; MRSA: methicillin-resistant *S. aureus*; MSSA: methicillin-susceptible *S. aureus*; MDR: multi-drug resistance; CRKP: carbapenem-resistant *K. pneumoniae*; CSKP: carbapenem-susceptible *K. pneumoniae*; CRPA: carbapenem-resistant *P. aeruginosa*; CSPA: carbapenem-susceptible *P. seruginosa*; CRAB: carbapenem-resistant *A. baumannii*; CSAB: carbapenem-susceptible *A. baumannii*; IRAB: imipenem-resistant *A. baumannii*; ISAB: imipenem-susceptible *A. baumannii*; ESBL: extended spectrum βlactamases; ICU: intensive care unit; LOS: length of stay; SD: standard deviation; IQR: interquartile range; Q: quartile.
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###### 

Studies describing hospital costs among patients with antibiotic resistance and multi-drug resistance.

  Author                                         Year   Bacteria                          Comparison Group        Sample Size                    Description of Cost   Mean (Median) Costs in 2015 USD   *p*-Value                                                 
  ---------------------------------------------- ------ --------------------------------- ----------------------- ------------------------------ --------------------- --------------------------------- --------------------------- ---------------- ------------ ---------
  Fu et al. \[[@B56-antibiotics-08-00115]\]      2014   *S. aureus*                       MRSA                    without infection              456                   706                               total hospital cost         (15,763)         \(2185\)     0.001
  Li et al. \[[@B70-antibiotics-08-00115]\]      2016   *S. aureus*                       MRSA                    MSSA                           14                    61                                total hospital cost         5305(319)        2658(352)    0.39
  Chen et al. \[[@B38-antibiotics-08-00115]\]    2016   *S. aureus*                       MRSA                    MSSA                           75                    78                                treatment cost              (23,933)         (19,905)     0.395
  46                                             46     treatment cost                    (19,718)                (19,538)                       0.935                                                                                                             
  Hu et al. \[[@B28-antibiotics-08-00115]\]      2014   gram-negative                     MDR                     non-MDR                        89                    165                               total hospital cost         (12,360)         (11,591)     \>0.05
  89                                             165    antibiotic cost                   \(1946\)                \(1397\)                       \<0.01                                                                                                            
  Long et al. \[[@B40-antibiotics-08-00115]\]    2015   gram-negative                     carbapenem resistance   carbapenem susceptibility      34                    34                                total treatment cost        11,206           6686         0.034
  Jiang et al. \[[@B57-antibiotics-08-00115]\]   2016   gram-positive/gram-negative       MDR                     non-MDR                        41                    41                                total hospital cost         (10,832)         \(6607\)     \<0.00
  Li et al. \[[@B58-antibiotics-08-00115]\]      2018   gram-positive/gram-negative       MDR                     susceptibility                 78                    78                                total hospital cost         1660             1093         \<0.001
  78                                             78     antibiotic cost                   485                     322                            \<0.001                                                                                                           
  Liu \[[@B60-antibiotics-08-00115]\]            2018   gram-positive/gram-negative       antibiotic resistance   without nosocomial infection   133                   133                               total hospital cost         20,222           3726         \<0.05
  Pan et al. \[[@B61-antibiotics-08-00115]\]     2018   gram-positive/gram-negative       MDR                     susceptibility                 102                   79                                total hospital cost         12,602           9793         \<0.001
  102                                            79     antibiotic cost                   952                     740                            \<0.001                                                                                                           
  Yang et al. \[[@B52-antibiotics-08-00115]\]    2009   gram-positive/gram-negative       resistance              non-resistance                 676                   732                               total hospital cost         11,035(4303)     2940(1103)   \<0.001
  676                                            732    antibiotic cost                   812(418)                274(119)                       \<0.000                                                                                                           
  Xing et al. \[[@B64-antibiotics-08-00115]\]    2017   gram-positive/gram-negative       MDR                     without infection              178                   178                               total hospital cost         (16,138)         \(1714\)     \<0.001
  Zhen et al. \[[@B69-antibiotics-08-00115]\]    2018   gram-positive/gram-negative       MDR                     non-MDR                        64                    37                                total hospital cost         21,164           6680         \<0.000
  64                                             37     antibiotic cost                   4001                    760                            \<0.000                                                                                                           
  Guo et al. \[[@B27-antibiotics-08-00115]\]     2017   *A. baumannii*                    MDR                     non-MDR                        122                   366                               total hospital cost         14,159(10,452)   7487(3759)   \<0.001
  Wu et al. \[[@B63-antibiotics-08-00115]\]      2018   *A. baumannii*                    MDR                     non-MDR                        65                    65                                total hospital cost         (24,897)         \(8823\)     \<0.01
  65                                             65     daily hospital cost               \(581\)                 \(688\)                        0.14                                                                                                              
  Cui et al. \[[@B39-antibiotics-08-00115]\]     2012   *A. baumannii*                    IRAB                    ISAB                           138                   138                               daily total hospital cost   \(591\)          \(338\)      \<0.01
  138                                            138    daily antibiotic cost             \(90\)                  \(55\)                         \<0.01                                                                                                            
  Zhen et al. \[[@B68-antibiotics-08-00115]\]    2017   *A. baumannii*                    CRAB                    CSAB                           2126                  854                               total hospital cost         30,575           19,783       \<0.000
  2126                                           854    antibiotic cost                   3047                    1692                           \<0.000                                                                                                           
  Chen et al. \[[@B43-antibiotics-08-00115]\]    2018   *P. aeruginosa*                   CRPA                    CSPA                           327                   472                               total hospital cost         \(925\)          \(482\)      \<0.001
  270                                            270    total hospital cost               \(868\)                 \(707\)                        0.015                                                                                                             
  327                                            472    daily hospital cost               \(36\)                  \(27\)                         \<0.001                                                                                                           
  270                                            270    daily hospital cost               \(34\)                  \(32\)                         0.045                                                                                                             
  Xu et al. \[[@B65-antibiotics-08-00115]\]      2017   *E. coli*                         MDR                     non-MDR                        969                   1940                              total hospital cost         3645             2071         \<0.001
  969                                            1940   antibiotic cost                   234                     154                            \<0.001                                                                                                           
  *K. pneumoniae*                                MDR    non-MDR                           186                     529                            total hospital cost   5132                              3178                        0.001                         
  186                                            529    antibiotic cost                   263                     246                            0.59                                                                                                              
  *Proteus mirabilis*                            MDR    non-MDR                           38                      60                             total hospital cost   6383                              2700                        \<0.001                       
  38                                             60     antibiotic cost                   271                     114                            0.001                                                                                                             
  *A. baumannii*                                 MDR    non-MDR                           53                      45                             total hospital cost   5446                              3100                        0.025                         
  53                                             45     antibiotic cost                   222                     136                            0.054                                                                                                             
  *P. aeruginosa*                                MDR    non-MDR                           13                      490                            total hospital cost   13,820                            3847                        \<0.001                       
  13                                             490    antibiotic cost                   884                     325                            \<0.001                                                                                                           
  *Enterobacter cloacae*                         MDR    non-MDR                           94                      166                            total hospital cost   7788                              3812                        \<0.001                       
  94                                             166    antibiotic cost                   386                     255                            0.01                                                                                                              
  *S. aureus*                                    MDR    non-MDR                           41                      237                            total hospital cost   4139                              2355                        0.006                         
  41                                             237    antibiotic cost                   223                     141                            0.007                                                                                                             
  coagulase-negative *Staphylococci*             MDR    non-MDR                           76                      184                            total hospital cost   9028                              3215                        \<0.001                       
  76                                             184    antibiotic cost                   362                     212                            \<0.001                                                                                                           
  Hu et al. \[[@B67-antibiotics-08-00115]\]      2010   *E. coli/Klebsiella spp*.         ESBL-positive           ESBL-negative                  32                    53                                total hospital cost         541              303          \<0.001
  32                                             53     cost of intravenous antibiotics   98                      40                             0.001                                                                                                             
  Meng et al. \[[@B44-antibiotics-08-00115]\]    2017   *E. coli*                         CREC                    CSEC                           49                    96                                total hospital cost         (12,670)         (10,290)     0.05
  without infection                              49     96                                total hospital cost     (12,670)                       \(2818\)              \<0.00                                                                                      
  Huang et al. \[[@B51-antibiotics-08-00115]\]   2018   *K. pneumoniae*                   CRKP                    CSKP                           237                   237                               total hospital cost         (21,170)         (11,313)     \<0.001
  237                                            237    total antibiotic cost             \(2253\)                \(1251\)                       \<0.01                                                                                                            
  237                                            237    hospital cost after infection     \(8912\)                \(6677\)                       0.003                                                                                                             
  237                                            237    antibiotic cost after infection   \(973\)                 \(573\)                        \<0.001                                                                                                           

*S. aureus*: *Staphylococcus aureus*; *A. baumannii*: *Acinetobacter baumannii*; *P. aeruginosa*: *Pseudomonas aeruginosa*; *K. pneumoniae*: *Klebsiella pneumoniae*; *E. coli*: *Escherichia coli*; MRSA: methicillin-resistant *S. aureus*; MSSA: methicillin-susceptible *S. aureus*; MDR: multi-drug resistance; CRKP: carbapenem-resistant *K. pneumoniae*; CSKP: carbapenem-susceptible *K. pneumoniae*; IRAB: imipenem-resistant *A. baumannii*; ISAB: imipenem-susceptible *A. baumannii*; CRAB: carbapenem-resistant *A. baumannii*; CSAB: carbapenem-susceptible *A. baumannii*; CRPA: carbapenem-resistant *P. aeruginosa*; CSPA: carbapenem-susceptible *P. seruginosa*; ESBL: extended spectrum βlactamases; CREC: carbapenem-resistant *E. coli*; CSEC: carbapenem-susceptible *E. coli*; USD: United States Dollars.
